Therapanacea SAS
About Therapanacea SAS
Therapanacea SAS is a healthcare AI company dedicated to transforming cancer care through science-driven clinical solutions. The company, a spin-off from Paris-Saclay University, leverages advanced mathematics, deep scientific expertise, and clinical collaboration to develop AI-powered software for more efficient and precise cancer treatment. Their flagship platform, ART-Plan™, is a web-based radiotherapy planning platform that is CE-marked and FDA-cleared.
ART-Plan™ automates and standardizes radiotherapy treatment planning by utilizing deep learning-based auto-segmentation algorithms, automated multi-modal image fusion modules, and synthetic pseudo-CT generation tools. This enables radiation oncologists, medical physicists, and dosimetry specialists to accelerate organ-at-risk and lymph node contouring, track real-time target adjustments, and execute high-precision adaptive radiotherapy workflows with minimal manual modification. The platform aims to augment physician decision-making by providing insights that would be challenging for an individual to derive alone, ultimately leading to safer, more personalized treatment pathways for patients, improved workflow efficiency for hospitals, and scalable propagation of best practices for clinicians.
Focus Areas
Business Intelligence
| Technology | Deep Learning, AI-based software platform, web-based solution, GPU workloads, multi-modal visualization, rigid and deformable registration |
What Physicians Need to Know
TheraPanacea's ART-Plan™ platform offers significant advantages for physicians by automating time-consuming and repetitive tasks in radiotherapy planning, such as contouring and image registration. This 'zero-click' automation can save up to 90% of manual effort, allowing clinicians to focus more on patient care and complex decision-making. The platform's ability to generate expert-level contours in minutes, perform seamless multimodal image fusion, and create pseudo-CTs from MR or CBCT images, empowers physicians to deliver more precise, efficient, and scalable treatment workflows. The adaptive radiotherapy capabilities, supported by AI-generated synthetic-CTs, provide decision-making support for adjusting treatment plans based on daily anatomical changes, potentially improving patient outcomes and reducing toxic side effects. TheraPanacea emphasizes a 'built with clinicians, for clinicians' approach, ensuring their solutions are integrated into existing workflows and validated through close collaboration with leading cancer centers worldwide. This focus on augmented clinical intelligence aims to standardize care, improve workflow efficiency, and enable high-quality clinical decision-making within existing treatment planning systems.
TheraPanacea's ART-Plan™ is designed to fit into existing radiotherapy workflows and is vendor-agnostic, allowing institutions to integrate their solutions into their current technology environments. The software supports the import, processing, and export of DICOM 3.0 compliant datasets, including various imaging modalities like CT, MR, PET-CT, 4D-CT, and CBCT. Their solutions are compatible with existing Treatment Planning Systems (TPS) for dose calculation, review, and approval. TheraPanacea also collaborates with technology partners like Brainlab, integrating their AI-powered segmentation software directly into Brainlab's Elements portfolio to enhance radiotherapy efficiency and offer more choices in segmentation for organs at risk.
What the Web Says
Therapanacea SAS is a medical technology company founded in 2017, known for its AI-powered software, ART-Plan, used in adaptive radiotherapy for cancer treatment. The software aims to optimize radiation delivery and minimize exposure to healthy tissues. While direct reviews for Therapanacea SAS as an employer or specifically on platforms like G2, Glassdoor, Capterra, or Reddit are limited, information regarding their product, ART-Plan, is available through FDA reviews and scientific literature. There appears to be some confusion in search results with other companies named "Panacea" or "TheraPlatform" which operate in different sectors (veterinary software, marketing project management, mental health software) and are not related to Therapanacea SAS.
Overall: MixedStrengths
- ART-Plan can significantly reduce treatment volumes and peripheral radiation doses in cancer patients.
- The device's adaptive capabilities allow for improved dose conformity and potential dose escalation while sparing adjacent organs.
- ART-Plan is software, not an implanted device, and does not have physical catheter, implant, or device sizes.
- It offers automatic solutions for delineation and multimodal image fusion, improving standardization and reducing user time.
- The software supports image-guided radiation therapy workflows.
- No significant adverse events have been highlighted in the available literature for ART-Plan.
Limitations
- Use of ART-Plan requires compatible imaging, treatment-planning, and radiation-delivery systems.
- A qualified radiation oncology team must review and approve adapted plans before treatment delivery.
- The software does not replace physician judgment, image-quality checks, treatment verification, or standard radiation-safety procedures.
- Limited public reviews available for Therapanacea SAS as an employer or on major review platforms.
Based on reviews from: art-plan - Therapanacea | FDA Evidence Review - LA Vascular, Did the EIC Accelerator Pay Off for TheraPanacea's Radiotherapy AI ..., art-plan v 2 2 0 - Therapanacea Sas | FDA Evidence Review, Therapanacea SAS April 19, 2023 Catherine Martineau-Huynh COO 7 bis boulevard Bourdon Paris, 75004 FRANCE Re: K230023/S001 - accessdata.fda.gov, Panacea Reviews 2026. Verified Reviews, Pros & Cons - Capterra, Panacea Reviews 2026. Verified Reviews, Pros & Cons - Capterra, Capterra: Reviews, Pricing, Features in 2026 - SoftwareSuggest, Panacea Software Pricing, Alternatives & More 2026 | Capterra, TheraPlatform Reviews 2026: Details, Pricing, & Features - G2
Last updated: 2026-10-26
Videos
News, demos, and interviews about Therapanacea SAS.
Videos load interactively. If none appear, search YouTube for Therapanacea SAS →
Press & Coverage
Frequently Asked Questions
Related Companies
A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]
Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]
Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]